|
Volumn 149, Issue 5, 2015, Pages 1465-1466
|
Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol
a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
HEMOGLOBIN;
HEPARIN;
LACTATE DEHYDROGENASE;
BIOLOGICAL MARKER;
BLOOD CLOTTING FACTOR 10A;
BLOOD CLOTTING FACTOR 10A INHIBITOR;
AGED;
BLOOD CLOTTING FACTOR 12 DEFICIENCY;
CASE REPORT;
CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE;
DOSE RESPONSE;
HEMOGLOBINURIA;
HEMOLYSIS;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
LETTER;
MALE;
PRIORITY JOURNAL;
ADVERSE EFFECTS;
BLOOD;
DRUG EFFECTS;
DRUG MONITORING;
HEART ASSIST DEVICE;
HEART FAILURE;
HEART LEFT VENTRICLE FUNCTION;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLISM;
PARTIAL THROMBOPLASTIN TIME;
PATHOPHYSIOLOGY;
PREDICTIVE VALUE;
PROCEDURES;
PROSTHESIS DESIGN;
TIME FACTOR;
TREATMENT OUTCOME;
ADMINISTRATION, INTRAVENOUS;
AGED;
BIOMARKERS;
DRUG MONITORING;
FACTOR XA;
FACTOR XA INHIBITORS;
HEART FAILURE;
HEART-ASSIST DEVICES;
HEMOLYSIS;
HEPARIN;
HUMANS;
MALE;
PARTIAL THROMBOPLASTIN TIME;
PREDICTIVE VALUE OF TESTS;
PROSTHESIS DESIGN;
TIME FACTORS;
TREATMENT OUTCOME;
VENTRICULAR FUNCTION, LEFT;
|
EID: 84929593954
PISSN: 00225223
EISSN: 1097685X
Source Type: Journal
DOI: 10.1016/j.jtcvs.2015.02.029 Document Type: Letter |
Times cited : (3)
|
References (5)
|